ITK and metastatic melanoma: It is not clear whether the lack of consistent improvement in the Th1:Th2 ratio is due to an inadequate exposure of lymphocytes to ibrutinib, or whether the immune milieu of metastatic melanoma patients drives Th2 differentiation in a manner that does not require ITK.